Evaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
A legfontosabb adatok
- Ki végzi
- LucasBio
- Hol
- Dél-Korea1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 5 fő, tervezett
- Kezdés
- 2026. ápr. 27.
- Várható befejezés
- 2027. aug. 14.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- LB-DTK-CMV
- A regiszteradat frissítve
- 2026. július 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with CMV retinitis, an eye infection caused by cytomegalovirus, that has not responded to antiviral drugs. They must have had a stem cell or organ transplant for a blood cancer, or strong immune-lowering treatment for an autoimmune disease.
- Életkor
- 19 years or older
- Nem
- All sexes can join
- A betegség stádiuma
- CMV retinitis that persists or worsens despite antiviral drugs, or ongoing CMV in the blood, or new CMV retinitis. People whose side effects limit the use of more than one antiviral drug can also join. People must be able to lower their steroid dose to 0.5mg/kg/day of Prednisolone (or an equivalent dose) or less.
- Korábbi kezelés
- Must have had a blood stem cell transplant or solid organ transplant for a blood cancer, or high-dose immune-lowering treatment for an autoimmune disease. Must have had antiviral treatment by mouth or vein, or injected into the eye. No ATG, Campath (Alemtuzumab) or similar T-cell antibodies within 28 days before the first dose. No donor lymphocyte infusion (DLI) within 28 days before the first dose.
- Biomarker vagy leletérték
- One way in is having CMV UL54 or UL97 mutations linked to antiviral resistance. Women who could become pregnant need a negative blood pregnancy test at screening.
A részvétel fő kizáró okai
- Hepatitis B, hepatitis C, tuberculosis, syphilis or other uncontrolled infections
- Uncontrolled high blood pressure or uncontrolled severe diabetes
- Severe liver damage (AST or ALT > 5 times the upper limit of normal) or eGFR < 30mL/min/1.73m^2
- Active cancer or uncontrolled return of cancer, or other uncontrolled eye diseases
- Pregnant or breastfeeding, or able to become pregnant without using proper birth control
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Patients aged 19 years or older who have been diagnosed with CMV retinitis and have undergone hematopoietic stem cell transplantation or solid organ transplantation for the treatment of hematologic malignancies, or have received high-dose immunosuppressive therapy for the treatment of autoimmune diseases, and who meet at least one of the following criteria:; Patients with persistent or progressive CMV retinitis despite systemic antiviral therapy or intravitreal antiviral treatment; Patients who have showed persistent CMV viremia despite systemic antiviral therapy or developed new CMV retinitis; Patients with CMV UL54 or UL97 mutations associated with antiviral resistance; Patients with adverse effects or toxicities limiting the administration of more than one systemic antiviral drug
- Patients who are pregnant and able to reduce their steroid dosage to 0.5mg/kg/day of Prednisolone (or an equivalent dose) or less
- For women of childbearing potential, those who tested negative on a pregnancy test (blood test) performed on the screening visit
- Individuals who have voluntarily decided to participate in this clinical study and have provided written consent to comply with the restrictions
- Individuals deemed suitable as study subjects through screening tests (vital signs, physical examination, medical and surgical history, electrocardiogram, laboratory tests, etc)
Ki nem vehet részt
- Individuals who have received treatment with ATG (Antithymocyte Globulin), Campath (Alemtuzumab), or other T-cell immunosuppressive monoclonal antibodies within 28 days prior to the first dose
- Patients who have received an investigational product from another clinical study within 24 weeks prior to administration of the investigational product in this study
- Patients with active malignant tumor or uncontrolled recurrence
- Patients with uncontrolled ophthalmic diseases other than CMV retinitis
- Individuals who meet any of the following criteria at the time of screening:; Uncontrolled hypertension; Systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite taking antihypertensive medication; Uncontrolled severe diabetes: Severe diabetes is defined as follows:; Severe hyperglycemia with HbA1C ≥ 10.0%; Individuals who have been hospitalized for diabetic ketoacidosis within the past 12 weeks; Individuals who have received emergency treatment or been hospitalized within the past 12 weeks for severe hypoglycemia (glucose <54 mg/dL) accompanied by seizures and loss of consciousness; Other viral infections; Hepatitis B Virus (HBV), Hepatitis C Virus (HCV); However, patients who are tested negative for HBsAg and positive for Anti-HBcAb are not subject to this exclusion criterion; Tuberculosis; Syphilis; Moderate or severe liver damage; Aspartate aminotransferase (AST) or Alanin aminotransferase (ALT) > 5 times the upper limit of normal (ULN); Chronic kidney disease; eGFR < 30mL/min/1.73m\^2; Other uncontrolled infections. However, the following cases are considered controlled infections and do not meet the exclusion criteria:; Bacterial infection: Patients must be undergoing definitive antibiotic treatment for the infection and must have shown no signs of progression of the infection for 72 hours prior to enrollment in this clinical study; Fungal infection: Patients must be receiving systemic antifungal therapy and must have shown no signs of infection progression for 1 week prior to enrollment in this clinical study
- Patients who have received donor lymphocyte infusion (DLI) within 28 days prior to the scheduled first dose
- Female subjects who are pregnant, breastfeeding, of childbearing potential, or not using appropriate contraceptive methods
- Patients with a life expectancy of less than 24 hours at the time of the screening visit
- Patients deemed ineligible for participation in this clinical study by the investigator
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this exploratory clinical study is to evaluate the safety and efficacy of Cytomegalovirus-Specific T cells (LB-DTK-CMV) to treat patients diagnosed with antiviral-resistant and refractory cytomegalovirus retinitis. The main questions it aims to answer are:
A teljes eredeti leírásKevesebb
* What adverse events occur after the infusion of LB-DTK-CMV? * What is the duration of efficacy following treatment? * Is there a clinically significant reduction in CMV viral load in plasma and aqueous humor after the infusion? * Is there a clinically significant improvement in clinical symptoms after the infusion?
Participants will:
* Receive two infusions of LB-DTK-CMV at 2x10\^7cells/m\^2 at two-week intervals beginning at the baseline visit (Cycle 1). * Take a three-week resting period following completion of Cycle 1. * Receive two infusions of LB-DTK-CMV at 2x10\^7cells/m\^2 at two-week intervals beginning three weeks after the last dose of Cycle 1 (Cycle 2).
A vizsgálat csoportja
- Experimental Group (All)A vizsgált kezelés
Kezelés: LB-DTK-CMV
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Exploratory Clinical Study of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 1.